Abstract Details

Title Lewy body dementia (LBD) prevalence and cholinesterase inhibitor use in Florida

Topic General Neurology

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-011

Objective To characterize the LBD population in Florida using a statewide Patient Centered Outcomes Research Institute (PCORI)-funded clinical data research network, OneFlorida Clinical Research Consortium (CRC).

Background LBD is the second most common dementia in the United States, however there is limited information about the characteristics of this population. Cholinesterase inhibitors are considered standard of care in LBD, but the frequency of use is not well reported.

Design/Methods Patients in the OneFlorida CRC with an ICD-9-CM 331.82 or ICD-10CM G31.83 diagnosis code during at least 1 encounter from January 2012 - March 2018 were included. Prevalence was calculated by comparing to the whole OneFlorida CRC sample. The gender distribution of LBD in Florida and racial/ethnic demographics were assessed. Frequency of acetylcholinesterase inhibitor use was assessed using prescription information (RXCui code).

Results 3664 individuals with a diagnosis of LBD between 2012 and 2018 were identified. Among 15 million patients in the OneFlorida CRC the prevalence of LBD was 0.02%. Males accounted for 55.7% of individuals diagnosed with LBD. The median age in this period was 77 years (range 40 to 105 years, IQR=12). LBD was most commonly diagnosed in individuals identifying as white (77.6%), followed by African American/black (10.8%) and Asian (1.1%). Almost 19% of the population identified as Hispanic. Less than half of individuals with LBD in Florida received a cholinesterase inhibitor during the examined period. Donepezil was most commonly prescribed (23.8%), followed by rivastigmine (11.5%), and galantamine (1%).

Conclusions LBD is diagnosed in individuals in Florida across racial-ethic categories. African-Americans account for a lower percent of LBD cases than the proportion of African-Americans in Florida (16%), suggesting that LBD may be underdiagnosed in this population. The male predominance seen is consistent with other population-based studies in LBD. Fewer than half of individuals with LBD received a cholinesterase inhibitor trial, a clear area to target improvement.

Authors/Disclosures
Bhavana U. Patel, DO (Bhavana Patel) PRESENTER	The institution of Dr. Patel has received research support from National Institute on Aging. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Question writer with ��ɫ��.
Melissa Armstrong, MD, MSc, FAAN, FAAN (UF Department of Neurology)	The institution of Dr. Armstrong has received research support from National Institutes of Health. The institution of Dr. Armstrong has received research support from Florida Department of Health. The institution of Dr. Armstrong has received research support from Lewy Body Dementia Association. The institution of Dr. Armstrong has received research support from The Michael J. Fox Foundation. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Clinical Trials Consortium. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Disease Cooperative Study. Dr. Armstrong has received personal compensation in the range of $500-$4,999 for serving as a DSMB member with National Institutes of Health. Dr. Armstrong has a non-compensated relationship as a Member, Scientific Advisory Council with Lewy Body Dementia Association that is relevant to AAN interests or activities.
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��